Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249366 · ClinicalTrials.gov registry record · Phase 4
Treatment of Alcohol Withdrawal in Hospital Patients
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 4
- Development phase
- 183
- Enrollment target
NCT00249366: Completed Phase 4 study, sponsored by Virginia Commonwealth University.
NCT00249366 is a Phase 4 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 183 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00249366, a Phase 4 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 183 participants
- Enrollment target
Study Summary
The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.
Primary Outcome
Difference in Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores between study arms
Interventions
- DRUG Lorazepam
- DRUG Lorazepam (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2001-04 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
What the finished NCT00249366 record still lists
NCT00249366 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Lorazepam is the first listed.
NCT00249366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00249366 about?
NCT00249366 is a clinical study titled "Treatment of Alcohol Withdrawal in Hospital Patients". The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.
What is the current status of trial NCT00249366?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 183 participants. The study started on 2001-04. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00249366?
The interventions under investigation include: Lorazepam (DRUG), Lorazepam (drug) (DRUG).
Who is sponsoring clinical trial NCT00249366?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00249366's enrollment target sits among peer trials
183 463rd of 2000 higher than 1,537 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia